Spondyloarthritis
Dr. Antoni Chan synovialjoints
2 years 11 months ago
Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA.
Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU
Dr. Rachel Tate uptoTate
2 years 11 months ago
Morning stiffness has the highest correlate to disease activity in pregnant AS patients, as demonstrated in Abs 0374. I will indeed be focusing on this much more for my patients. #ACR22 #ACRbest @RheumNow https://t.co/9bmlQtGsLH https://t.co/qrxebQ6Ow1
Aurelie Najm AurelieRheumo
2 years 11 months ago
@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D.
Not so surprising considering higher ratio for Fibromyalgia in W
ASDAS not asso w/ gender in AxSPA.
https://t.co/kBxvAi5qZw
Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l
Catherine Sims, MD DrCassySims
2 years 11 months ago
Xeljanz use in AS #ACR22 (@pfizer sponsored) @RheumNow
-Included patients with at least bilateral grade 2 SI or grade 3/4 unilateral SI
-5mg BID Xeljanz
-Significantly more patients had ASAS20/40 response, CRP reduction, & QOL, vs. placebo
-Onset of action noticed at 2 weeks https://t.co/DisKpgR0pt
Patricia Harkins DrTrishHarkins
2 years 11 months ago
⬆️ correlation between BASDAI + ASQoL in 🙋♂️ vs 🙋♀️
What does this mean?
❓low disease activity in 🙋♀️ resulting in more marked ⬇️ in QoL❓
OR
❓Is there a need for gender stratified tools of disease activity❓
Abst#0406
#ACR22 @RheumNow @Sineadm15
Akhil Sood MD AkhilSoodMD
2 years 11 months ago
Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis
- Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement
https://t.co/mGAn0Eel1O
@RheumNow #ACR22 https://t.co/qtJsavtG9z
Aurelie Najm AurelieRheumo
2 years 11 months ago
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
Adela Castro AdelaCastro222
2 years 11 months ago
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
A new treatment for AxSpA that has come on the scene are JAK inhibitors. In clinic, considerations for JAKi use are body mass index, smoking status, prior use of biologics and patients with high inflammatory states such as high CRP and inflammatory change on MRI scan of the spine and sacroiliac joints. There are further studies at #ACR22 which help answer these questions.
TheDaoIndex KDAO2011
2 years 11 months ago
“Expert rheumatologist opinion remains the gold standard!” – Dr. J Scher on diagnosis of #axSpa
I would like to think this quote applies to everything, not just to axSpa (-my own opinion)
#ACRreview #ACR22 @rheumnow https://t.co/zpwQwXA8o2
When it comes to Spondyloarthritis we have numerous disease activity measures and much debate regarding best practices. When it comes to determining which to use in clinic, discrepancies occur. Do our activity measures truly represent disease? Are there some measures best suited to different populations? Does BASDAI work for women?
The pharmaceutical companies have will showcase their featured clinical trials and abstracts at ACR 2022. These are their best studies for you to review and evaluate as part of your to-do list. In the least, you should be familiar with the names and objectives of some of these studies as they will be discussed and mentioned throughout the meeting.
Abbvie
Dr. John Cush RheumNow
2 years 11 months ago
Update: axSpA Recommendations
https://t.co/KaBb11WLQD https://t.co/8kIaa0WuvM
As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. My attention this year is in research being presented in these three areas: ankylosing spondylitis; lupus management and treatment; and, subclinical RA.
Poster Hall